GlassScriptPhysician profile
Henry B Hwu
NPI 1891843702
$3,578.00
in general payments reported to CMS, 2019-2025
22 companies · $1,037 in 2025
The $1,037 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $143 · 2021: $650 · 2022: $635 · 2023: $149 · 2024: $445 · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,630.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $574.31 | 2023-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $449.79 | 2021-2022 | |
| Abbvie INC. | $334.26 | 2019-2025 | |
| Gilead Sciences, INC. | $323.16 | 2020-2022 | |
| Davol INC. | $281.89 | 2019-2024 | Phasix Mesh |
| Vertex Pharmaceuticals Incorporated | $241.20 | 2025 | |
| Phathom Pharmaceuticals, INC. | $181.86 | 2024-2025 | Voquezna |
| Csa Medical, INC | $131.00 | 2019 | |
| Nestle Healthcare Nutrition INC. | $123.41 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $123.29 | 2021 | |
| Lucid Diagnostics INC. | $118.61 | 2022 | |
| Lilly USA, LLC | $118.45 | 2025 | |
| Janssen Scientific Affairs, LLC | $114.52 | 2022 | |
| Celltrion USA INC. | $94.88 | 2025 | Zymfentra |
| Conmed Corporation | $77.11 | 2025 | Airseal, Conmed Specimen Retrieval |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aroa Biosurgery Incorporated | $70.10 | 2025 | |
| Ethicon US, LLC | $56.47 | 2024 | Echelon; Endopath |
| Acell, INC. | $45.96 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $42.01 | 2022 | |
| Redhill Biopharma INC. | $30.50 | 2024 | Talicia |
| Mallinckrodt Enterprises LLC | $26.33 | 2019 | |
| Olympus America INC. | $18.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Hwu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.